KODIAK SCIENCES INC (KOD)
Health Care · Biotechnology · NASDAQ
Kodiak Sciences is a clinical-stage biotech company developing next-generation, high-durability retinal medicines using its proprietary Antibody Biopolymer Conjugate (ABC) platform.
What KODIAK SCIENCES INC does
Kodiak Sciences is a precommercial biotechnology company focused on researching, developing, and commercializing therapeutics to treat high-prevalence retinal diseases. The company utilizes its proprietary Antibody Biopolymer Conjugate (ABC) platform to develop biologics designed for high immediacy and extended treatment durability. Its lead pipeline assets include tarcocimab, KSI-501, and KSI-101, targeting conditions such as wet AMD, diabetic retinopathy, retinal vein occlusion, and macular edema secondary to inflammation.
Themes: retinal health, ophthalmology therapeutics, anti-VEGF therapies, biologic manufacturing, AI in healthcare, precision medicine
Fundamentals
- Price$38.33 as of 2026-08-21 close
- Market cap$2.4B as of 2026-08-21
- 1-year return+294.7% 2025-08-21 close $9.71 → 2026-08-21 close $38.33
- P/En/a earnings data not available
- ROE-253.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta2.22 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How KOD compares in its sector
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
KOD is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
50.7 #732 of 1,704 scored · #129 of 240 in Health Care
Catalysts 67th: analysts have raised their average price target by 6.2% since the prior reading; volume and participation 53rd: trading volume is about normal versus its 30-day average; weakest is momentum 39th: its RSI momentum gauge is in neutral territory.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How KODIAK SCIENCES INC looks technically
KODIAK SCIENCES INC (KOD) is trading 19.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 257 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative). It just made a new 20-day low, its first since 2026-07-07, breaking below its recent trading range. It is 19.9% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 19.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +19.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $39.56 | $39.56 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $32.07 | $32.07 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 257 trading days ago — a "golden cross", a bullish long-term signal | 257 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend | 18.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 41.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($36.35 to $46.87) — its "stochastic" reading is 19 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 18.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $47.84 | $47.84 |
|---|---|---|
| From the 52-week high | it is 19.9% below its 52-week high (its highest price of the past year) | -19.9% |
| Above the 52-week low | it is 362.4% above its 52-week low (its lowest price of the past year) | +362.4% |
| Below the 52-week high | it is 19.9% below its highest point of the past year | 19.9% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-07-07, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 12 trading days ago | 12 sessions |
| All-time high | its highest closing price on record is $171.21 (set on 2021-02-10) | $171.21 |
| Given back of the 52-week move | over the past year its closes ranged ($8.55 to $46.44), and it has given back roughly a quarter of its rise from last year’s low — 21% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $21.81 to $23.02. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 21.4% |
| From the all-time high | it is 77.6% below its all-time high | -77.6% |
| Nearest price level | it is trading 24.3% above a support level at $29.03 — a price it turned at twice since 2026-02-25, most recently on 2026-06-09. Since 2024-08-21 it has 4 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -24.3% |
| All-time low | its lowest closing price on record is $1.37 (set on 2023-10-27) | $1.37 |
| Above the all-time low | it is 2697.8% above its all-time low | +2,698% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 81% of it) | 19th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.89 between its high and its low — about 7.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.89 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $37.95 and $45.40 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $37.95 – $41.68 – $45.40 |
| Typical daily range (% of price) | its price moves about 7.6% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.5% |
| Stretch from the 200-day average | it is trading 2.2 daily ranges above its 200-day average price (19.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.86× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 6.2% since the prior reading | +6.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bearish engulfing | today it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | today |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.4% |
|---|---|---|
| Gap filled | a 2.6% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 5 sessions in a row, a -7.3% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 5 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 12.0 percentage points (the stock lost 9.6% while the market gained 2.3%) | -12.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 0.6 percentage points (the stock gained 2.5% while the market gained 3.1%) | -0.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 40.6 percentage points (the stock gained 51.6% while the market gained 11.1%) | +40.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 274.3 percentage points (the stock gained 294.7% while the market gained 20.5%) | +274.3% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thin, spanning 1.3% of the share price, which is taken to mean a barrier that gives way easily. | 0.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 9% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $35.08 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | +9.3% |
|---|
Price levels it has turned at before
KOD last closed at $38.33 on 2026-08-21. Since 2024-08-21 it has turned at 4 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $29.03 | Support | 24.3% below the last close | turned there twice · 2026-02-25 to 2026-06-09 |
| $21.02 | Support | 45.2% below the last close | turned there three times · 2025-10-30 to 2026-03-24 |
| $11.36 | Support | 70.4% below the last close | turned there twice · 2024-12-26 to 2025-08-15 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke down to a new 20-day low · trendless / choppy (low ADX) · Analyst price target recently RAISED · beating the market · Printed a bearish engulfing pair | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.17 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$69.00 range $56.00 – $85.00; median $66.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KOD
- Consensus EPS estimate-$1.00 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Failure to obtain regulatory approval for clinical candidates in a timely manner or at all.","Heavy reliance on a small number of investigational programs and a single proprietary platform.","Significant liquidity and capital requirements to fund ongoing late-stage clinical trials and commercial preparation."]
What changed in the latest 10-Q
AI-assisted comparison of KOD's 10-Q filed 2026-05-07 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Added language in opening paragraph: 'and that we may make from time to time' (newer version states 'that we may make from time to time' vs older version's 'those may make from time to time')
- Added specific reference to DAYLIGHT clinical trial in tarcocimab BLA submission context: 'we may need to delay submission which would delay review and potential approval'
- Added detailed description of DAYBREAK trial's AI-based dosing tool: 'our DAYBREAK trial uses an AI-based tool to measure retinal fluid and individualize dosing, and this dosing may not be incorporated into labeling or may require separate FDA review of the AI-based tool'
- Added reference to KSI-501 as subject of development discontinuation decisions alongside tarcocimab and other candidates
- Removed:
- Removed asterisk (*) notation indicating new or changed risk factors from the 2025-11-13 filing
- Removed phrase 'very limited operating history' (changed to 'limited operating history')
- Removed explicit reference to 'Phase 1b APEX clinical trial of KSI-101 in patients with DME and patients with MESI' and the Phase 3 GLOW2 trial description
- Removed language 'will be heavily dependent' changed to 'are heavily dependent'
- Removed phrase 'the results of planned or pending clinical studies' from the heading context
- Removed reference to safety or efficacy changes in earlier version and replaced with expanded FDA label discussion
- Removed 'We have never submitted a BLA, and even if GLOW1, GLOW2, BEACON, DAYLIGHT or DAYBREAK' language detail about specific trials
- Removed detailed description of Phase 1 KSI-501 study and enrollment completion language
- Removed phrase 'of tarcocimab' from section title about pivotal study failures
- Removed reference to 'two other trials that were then underway' description of tarcocimab development resumption
- Reworded:
- Changed 'very limited operating history' to 'limited operating history' in heading
- Changed 'Our prospects will be heavily dependent on' to 'Our prospects are heavily dependent on' (present tense vs future tense)
- Changed section heading from 'The failure of pivotal studies of tarcocimab to meet their primary efficacy endpoints may lead us to pause' to 'The failure of pivotal studies to meet their primary efficacy endpoints may lead us to pause' (removed 'of tarcocimab')
- Changed 'including KSI-501, based on future information such as in process or completed clinical trial results' vs older 'based on future information or trials results'
- Changed description of tarcocimab development resumption from 'we resumed the development of tarcocimab in November 2023 following the outcomes of two other trials that were then underway' to 'We resumed further development of tarcocimab in November 2023 following the outcomes of Year 1 data from the Phase 3 BEACON study in patients with RVO and the Phase 3 GLOW1 study of patients with DR'
- Notes:
- The newer filing text is truncated at the end ('...even if our planned additional trials are succes'), preventing full comparison of the final section
- The older filing similarly shows truncation ('Rese'), preventing assessment of complete section content
- Comparison is limited to the provided excerpt portions of the MD&A section
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($1M) — 1 selling insider
- Last 180 days0 buys · 6 sells ($2M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-04. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KOD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding KOD as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,706,829
- Reported value $293,784,331
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
KOD had 10,229,369 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
KOD had 16.3% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 20.61 days to cover at the same settlement.
- Reported short interest (shares) 10,229,369
- Short interest (% of shares outstanding) 16.3%
- Prior settlement (shares) 10,415,363
- Reported change -1.79%
- Days to cover (reported) 20.61
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Regeneron Pharmaceuticals (REGN)
- Roche (RHHBY)
- Novartis (NVS)
- Bausch + Lomb (BLCO)
- Apellis Pharmaceuticals (APLS)
- Iveric Bio (acquired by Astellas)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KOD vs…
KODIAK SCIENCES INC is found in…
Frequently asked questions
What does KODIAK SCIENCES INC (KOD) do?
Kodiak Sciences is a precommercial biotechnology company focused on researching, developing, and commercializing therapeutics to treat high-prevalence retinal diseases. The company utilizes its proprietary Antibody Biopolymer Conjugate (ABC) platform to develop biologics designed for high immediacy and extended treatment durability.
What sector is KODIAK SCIENCES INC (KOD) in?
KODIAK SCIENCES INC (KOD) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are KODIAK SCIENCES INC's (KOD) competitors?
Notable peers of KODIAK SCIENCES INC (KOD) include Regeneron Pharmaceuticals, Roche, Novartis, Bausch + Lomb and Apellis Pharmaceuticals. This peer set is informational only — not financial advice.
Is KODIAK SCIENCES INC (KOD) overbought or oversold right now?
KODIAK SCIENCES INC (KOD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KOD come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.